May. 6 at 12:32 PM
RBC Capital⬆️the PT on
$CYTK to
$119 (was
$101) and reiterated at an Outperform rating.
$EWTX $BMY
SNY NVS LLY AZN JNJ AMGN MRK
Here's what RBC Capital said in its note:
CYTK reported their 1Q26 earnings and we had a chance to catch up with mgmt.
We think that investors have not yet fully priced in the speed of Myqorzo's growth and peak U.S. opportunity in oHCM, where new patient starts are showing very promising trends, nor ACACIA's substantial opportunity in nHCM where we est. ~
$1.3B in sales by 2035.
With the company transitioning from the clinical to the commercial stage, we think this is worth a re-rating, and we look for upside on launch execution and potential M&A optionality - and we would be buyers. Price target to
$119 (from
$101) on model updates.
